Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Bristol-Myers Squibb Co. pages available for free this week:
- Analysis of Solvency Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Geographic Areas
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Return on Assets (ROA) since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
- Analysis of Revenues
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Bristol-Myers Squibb Co. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
The profitability metrics exhibit considerable fluctuation over the five-year period. Initial stability gives way to significant volatility, culminating in substantial shifts in the final two years. A general observation is a decline in margins followed by a recovery, though not to initial levels, alongside dramatic swings in return ratios.
- Gross Profit Margin
- The gross profit margin demonstrates a slight downward trend from 78.57% in 2021 to 76.24% in 2023. This decline accelerates in 2024, falling to 71.08%, and remains at that level through 2025. This suggests increasing costs of goods sold relative to revenue.
- Operating and Net Profit Margins
- Operating profit margin initially improves from 15.91% to 17.96% before decreasing to 16.18% in 2023. A substantial decline is then observed in 2024, resulting in a negative margin of -15.50%. A strong recovery occurs in 2025, with the margin rising to 20.75%. The net profit margin follows a similar pattern, moving from 15.08% to 13.71%, then to 17.83%, before plummeting to -18.53% in 2024. It partially recovers to 14.64% in 2025, though remaining below the 2021 and 2022 levels. The divergence between gross and operating/net margins indicates significant changes in operating expenses.
- Return on Equity (ROE)
- Return on equity shows an increasing trend from 19.46% to 27.27% through 2023, indicating increasing profitability relative to shareholder equity. However, 2024 sees a dramatic decrease to -54.78%, likely driven by the net loss. A substantial rebound to 38.19% occurs in 2025, suggesting a significant recovery in net income and/or changes in equity structure.
- Return on Assets (ROA)
- Return on assets mirrors the trend in ROE, increasing from 6.40% to 8.43% before experiencing a sharp decline to -9.66% in 2024. A partial recovery to 7.83% is observed in 2025. This indicates that the efficiency with which assets are used to generate profit has fluctuated considerably.
The pronounced negative values in 2024 for operating profit margin, net profit margin, ROE, and ROA suggest a particularly challenging year. The subsequent recovery in 2025 is notable, but the profitability ratios have not fully returned to their earlier levels. The volatility observed across all metrics warrants further investigation into the underlying drivers of these changes.
Return on Sales
Return on Investment
Gross Profit Margin
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Gross margin | ||||||
| Revenues | ||||||
| Profitability Ratio | ||||||
| Gross profit margin1 | ||||||
| Benchmarks | ||||||
| Gross Profit Margin, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Gross profit margin = 100 × Gross margin ÷ Revenues
= 100 × ÷ =
2 Click competitor name to see calculations.
The gross profit margin exhibited a declining trend over the five-year period. While initially high, the metric decreased from 78.57% in 2021 to 71.08% in both 2024 and 2025. This decline occurred alongside relatively stable revenue figures, with a slight increase observed in the later years.
- Gross Profit Margin Trend
- From 2021 to 2022, the gross profit margin experienced a modest decrease, moving from 78.57% to 78.04%. The rate of decline accelerated between 2022 and 2023, with the margin falling to 76.24%. A more substantial decrease was then observed between 2023 and 2024, dropping to 71.08%, and remained constant through 2025.
- Revenue and Gross Margin Relationship
- Revenues remained relatively consistent between 2021 and 2023, fluctuating around the $46 billion mark. A noticeable increase in revenues occurred between 2023 and 2024, reaching $48.3 billion, and remained near this level in 2025 at $48.194 billion. Despite this revenue increase in the latter years, the gross profit margin did not improve, indicating that the cost of goods sold increased at a faster rate than revenue.
- Gross Margin (US$ in millions)
- The gross margin in US$ millions decreased from $36.445 billion in 2021 to $34.258 billion in 2025. This absolute decline in gross margin, coupled with the percentage decline in gross profit margin, suggests increasing production costs or decreasing selling prices, or a combination of both.
The stabilization of the gross profit margin at 71.08% in the final two years of the period suggests a potential leveling off of cost pressures or pricing adjustments. However, the overall trend indicates a weakening of profitability from a gross margin perspective.
Operating Profit Margin
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Operating income (loss) | ||||||
| Revenues | ||||||
| Profitability Ratio | ||||||
| Operating profit margin1 | ||||||
| Benchmarks | ||||||
| Operating Profit Margin, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Operating Profit Margin, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Operating Profit Margin, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Operating profit margin = 100 × Operating income (loss) ÷ Revenues
= 100 × ÷ =
2 Click competitor name to see calculations.
The operating profit margin exhibited considerable fluctuation over the five-year period. Initial years demonstrated a positive trend, followed by a significant downturn and subsequent recovery.
- Overall Trend
- From 2021 to 2022, the operating profit margin increased from 15.91% to 17.96%, indicating improved operational efficiency or pricing power. This positive momentum continued, albeit at a slower pace, with a margin of 16.18% reported in 2023. However, 2024 witnessed a dramatic shift, with the operating profit margin plummeting to -15.50%, signifying substantial operational losses. A strong recovery was then observed in 2025, with the margin rebounding to 20.75%, exceeding the levels seen in prior years.
- Key Observations
- The most striking feature is the negative operating profit margin in 2024. This suggests a significant issue with cost control, revenue generation, or a combination of both during that year. The subsequent recovery in 2025 is noteworthy and warrants further investigation to understand the drivers behind this improvement. The initial increase from 2021 to 2022 suggests successful strategies were in place, but these were evidently disrupted in 2024.
- Relationship to Operating Income and Revenues
- The operating profit margin’s trajectory closely mirrors the changes in operating income. The decline in 2024 corresponds with a substantial operating loss, while the return to profitability in 2025 aligns with a positive operating income figure. Revenues remained relatively stable between 2021 and 2023, with a slight increase observed in 2024 and 2025. This suggests that revenue fluctuations were not the primary driver of the margin’s volatility; rather, changes in operating income had a more pronounced effect.
Further analysis is recommended to determine the underlying causes of the 2024 downturn and the factors contributing to the 2025 recovery. Investigating specific cost components and revenue streams would provide a more granular understanding of these shifts.
Net Profit Margin
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net earnings (loss) attributable to BMS | ||||||
| Revenues | ||||||
| Profitability Ratio | ||||||
| Net profit margin1 | ||||||
| Benchmarks | ||||||
| Net Profit Margin, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Net Profit Margin, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Net Profit Margin, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Net profit margin = 100 × Net earnings (loss) attributable to BMS ÷ Revenues
= 100 × ÷ =
2 Click competitor name to see calculations.
The net profit margin exhibited considerable fluctuation over the five-year period. Initial values demonstrated a generally positive trend, followed by a significant downturn and subsequent recovery.
- Overall Trend
- The net profit margin began at 15.08% in 2021, decreased to 13.71% in 2022, and then increased substantially to 17.83% in 2023. A dramatic shift occurred in 2024, with the margin falling to -18.53%, indicating a substantial net loss relative to revenue. The margin partially recovered in 2025, reaching 14.64%.
- Year-over-Year Changes
- From 2021 to 2022, a decrease of 1.37 percentage points in the net profit margin was observed. This was followed by a positive change of 4.12 percentage points from 2022 to 2023. The most significant change occurred between 2023 and 2024, with a decline of 36.36 percentage points. A subsequent increase of 33.17 percentage points was noted from 2024 to 2025.
- Relationship to Net Earnings and Revenues
- The fluctuations in net profit margin directly correlate with changes in net earnings and revenues. While revenues remained relatively stable between 2021 and 2023, the increase in net earnings contributed to the improved margin in 2023. The substantial net loss in 2024, despite a revenue increase, drove the margin sharply negative. The return to profitability in 2025, coupled with consistent revenue, resulted in a partial recovery of the net profit margin.
The volatility in the net profit margin suggests underlying factors significantly impacting profitability. The negative margin in 2024 warrants further investigation to understand the drivers of the substantial loss.
Return on Equity (ROE)
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net earnings (loss) attributable to BMS | ||||||
| Total BMS shareholders’ equity | ||||||
| Profitability Ratio | ||||||
| ROE1 | ||||||
| Benchmarks | ||||||
| ROE, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| ROE, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| ROE, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
ROE = 100 × Net earnings (loss) attributable to BMS ÷ Total BMS shareholders’ equity
= 100 × ÷ =
2 Click competitor name to see calculations.
The Return on Equity (ROE) exhibited significant fluctuations over the five-year period. Initial increases were followed by a substantial decline and subsequent recovery, indicating considerable volatility in profitability relative to shareholder investment.
- Overall Trend
- ROE began at 19.46% in 2021 and increased to 20.37% in 2022, suggesting improving profitability for shareholders. This positive trend continued with a marked increase to 27.27% in 2023. However, 2024 witnessed a dramatic reversal, with ROE plummeting to -54.78%. A strong recovery was then observed in 2025, with ROE rising to 38.19%.
- Net Earnings Impact
- Net earnings attributable to the company generally increased from 2021 to 2023, aligning with the rising ROE during that period. The substantial loss reported in 2024, with net earnings at -8,948 US$ millions, directly contributed to the negative ROE observed that year. The return to positive net earnings in 2025, at 7,054 US$ millions, drove the subsequent recovery in ROE.
- Shareholders’ Equity Impact
- Total shareholders’ equity decreased from 35,946 US$ millions in 2021 to 29,430 US$ millions in 2023. While decreasing equity generally amplifies ROE when earnings are positive, the significant reduction in equity in 2024, down to 16,335 US$ millions, exacerbated the negative impact of the net loss, resulting in the exceptionally low ROE. A modest increase in equity to 18,473 US$ millions in 2025 partially offset the negative impact of the prior year’s loss on the ROE calculation.
The considerable swing in ROE highlights the sensitivity of this metric to both net income and shareholder equity. The negative ROE in 2024 warrants further investigation to understand the underlying causes of the substantial loss and the factors contributing to the decrease in shareholder equity.
Return on Assets (ROA)
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net earnings (loss) attributable to BMS | ||||||
| Total assets | ||||||
| Profitability Ratio | ||||||
| ROA1 | ||||||
| Benchmarks | ||||||
| ROA, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| ROA, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| ROA, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
ROA = 100 × Net earnings (loss) attributable to BMS ÷ Total assets
= 100 × ÷ =
2 Click competitor name to see calculations.
The Return on Assets (ROA) exhibited considerable fluctuation over the five-year period. Initial increases were followed by a substantial decline and subsequent recovery.
- Overall Trend
- The ROA demonstrated an increasing trend from 2021 to 2023, peaking at 8.43% in 2023. This was followed by a significant decrease in 2024, resulting in a negative ROA of -9.66%. The ROA partially recovered in 2025, reaching 7.83%.
- Initial Growth (2021-2023)
- From 2021 to 2023, the ROA increased from 6.40% to 8.43%. This growth coincided with increasing net earnings attributable to the company, while total assets remained relatively stable, decreasing slightly from 2021 to 2023. The increase in ROA suggests improved efficiency in utilizing assets to generate profit during this period.
- Significant Decline (2024)
- In 2024, the ROA experienced a dramatic decline to -9.66%. This was primarily driven by a substantial net loss of US$8,948 million, while total assets continued to decrease, albeit at a slower rate. The negative ROA indicates that the company’s assets generated a loss during the year.
- Partial Recovery (2025)
- The ROA showed a partial recovery in 2025, rising to 7.83%. This improvement was attributable to a return to net earnings of US$7,054 million, despite a continued decrease in total assets. While the ROA recovered, it did not reach the levels observed prior to 2024.
The volatility in ROA highlights the sensitivity of the metric to changes in net earnings. The substantial loss in 2024 had a disproportionately negative impact, demonstrating the importance of profitability in driving asset utilization efficiency.